Simplifying Global Compliance
EMA Considers Ways to Evaluate Non-Genotoxic Drug Impurities
International Pharmaceutical Regulatory Monitor
Drug sponsors should assess the safety of non-genotoxic impurities (NGIs) in chemically synthesized drugs on a case-by-case basis, the EMA’s Committee for Medicinal Products for Human Use suggests in a draft reflection paper released for stakeholder comment.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor
Buy This Article Now
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing